An interview with a UK-based key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and uproleselan.
Global Hematology Market (2023-2028) by Product, Reagent, Application, End User, and Geography, Competitive Analysis, Impact of Economic Slowdown & Impending Recession with Ansoff Analysis
- Report
- 194 Pages
- Global
